




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Cardio-Oncology</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=a111dd2d-31c2-4097-b779-01457a536a5e</link>
        <description>Clinical Topic Feed: Cardio-Oncology</description>
        <language>en</language>

        

                <item>
                    <title>ACC Featured Jobs For September 2026</title>
<link>/Latest-in-Cardiology/Articles/2022/01/01/01/01/ACC-Featured-Jobs</link>                    <description>Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career!</description>
                    <pubdate>1788305160000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>FINE-HEART Post-Hoc Analysis Shows Finerenone Benefits Patients With CKM Syndrome Regardless of Cancer History</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/08/25/13/59/FINE-HEART-Post-Hoc-Analysis</link>                    <description>In patients with cardio-kidney-metabolic (CKM) syndrome, comorbid cancer was frequent and independently associated with worse outcomes but did not affect the treatment benefit of finerenone, according to a post-hoc analysis of the FINE-HEART pooled analysis published Aug. 18 in EHJ.</description>
                    <pubdate>1787759040000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACCEL Lite: Umbrella: Cardioprotection During Treatment</title>
<link>/Latest-in-Cardiology/Articles/2026/08/24/16/23/accel-lite-24aug2026</link>                    <description>In this interview, Dipti Itchhaporia MD, MACC and Ana Barac, MD, PhD, FACC discuss Umbrella: Cardioprotection During Treatment.</description>
                    <pubdate>1787674980000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Cardiotoxicity Risk With Combination Immune Checkpoint Inhibitor and FOLFOX Therapies For Colon Cancer: Review of the ATOMIC Findings</title>
<link>/Latest-in-Cardiology/Articles/2026/08/03/15/28/Cardiotoxicity-Risk</link>                    <description>Immune checkpoint inhibitors (ICIs) are revolutionary oncologic therapies used frontline in several malignant neoplasms, including non&#226;€“small cell lung cancer, melanoma, renal cell carcinoma, bladder cancer, and colorectal cancer.</description>
                    <pubdate>1785780720000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Ten Points to Remember From the Recent AHA Scientific Statement on &quot;Cardiovascular Toxicity in Patients Treated for Childhood Cancer&quot;</title>
<link>/Latest-in-Cardiology/Articles/2026/05/26/13/15/Ten-Points-to-Remember</link>                    <description>Pediatric cardio-oncology has expanded in scope over the past several decades to address the ever-increasing issues related to cardiovascular disease (CVD) in patients with and survivors of cancer, related both to treatment modalities and the disease itself.</description>
                    <pubdate>1779816420000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Management of Checkpoint Inhibitor Myocarditis in the CCU</title>
<link>/Latest-in-Cardiology/Articles/2026/03/12/10/54/Management-of-Checkpoint-Inhibitor-Myocarditis-in-the-CCU</link>                    <description>A 75-year-old man with a history of remote anterior ST-segment elevation myocardial infarction and stage IV malignant melanoma treated with combination immunotherapy (ipilimumab/nivolumab) presented to the oncology clinic with 3 days of exertional dyspnea and 24 hours of diplopia and neck weakness.</description>
                    <pubdate>1773320700000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>The Role of Exercise in Cardio-Oncology</title>
<link>/Latest-in-Cardiology/Articles/2026/01/23/18/21/The-Role-of-Exercise-in-Cardio-Oncology</link>                    <description>As cancer survival rates improve due to advances in treatment, new challenges have emerged; one of the most serious is cancer therapy&#226;€“related cardiac dysfunction (CTRCD) and subsequent cardiovascular disease (CVD) among survivors of cancer.</description>
                    <pubdate>1769429520000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Top 2025 ACC Content</title>
<link>/Latest-in-Cardiology/Articles/2026/01/06/18/47/eagles-eye-view-07jan2025</link>                    <description>In this episode, Dr. Eagle looks back at 2025 and explores some of the significant developments that show how the College is responding to changes in the way we evaluate, manage, and follow patients with various types of cardiovascular disorders.</description>
                    <pubdate>1767798000000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Top ACC Content in 2025</title>
<link>/Latest-in-Cardiology/Articles/2025/12/19/18/18/Top-ACC-Content-in-2025</link>                    <description>The most popular ACC.org content items of 2025.</description>
                    <pubdate>1766455200000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Weight Reversal Post Tirzepatide Withdrawal </title>
<link>/Latest-in-Cardiology/Articles/2025/12/17/14/32/eagles-eye-view-17dec2025</link>                    <description>In this week&#226;€™s View, Dr. Eagle&#226;€&#175;looks&#226;€&#175;at the DANISH trial extended follow-up, evaluating which patients benefit most from primary prevention implantable cardioverter defibrillator (ICD) implantation.</description>
                    <pubdate>1765982040000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>